Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/11/2023 | $6.00 | Buy | H.C. Wainwright |
| 8/14/2023 | $2.75 → $3.50 | Underweight → Neutral | Piper Sandler |
| 6/22/2023 | $6.00 | Overweight | Cantor Fitzgerald |
| 5/16/2022 | $10.00 → $4.00 | Overweight → Underweight | Piper Sandler |
| 10/29/2021 | $17.00 | Outperform | Cowen & Co. |
| 9/24/2021 | $16.00 | Outperform | Oppenheimer |
| 9/22/2021 | $19.00 | Buy | BTIG |
| 9/16/2021 | $17.00 | Overweight | Piper Sandler |
8-K - Humacyte, Inc. (0001818382) (Filer)
8-K - Humacyte, Inc. (0001818382) (Filer)
424B3 - Humacyte, Inc. (0001818382) (Filer)
DURHAM, N.C., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, will release its financial results for the second quarter ended June 30, 2024, on Tuesday, August 13, 2024. Management will host a webcast and conference call at 8:30 a.m. ET to discuss recent corporate updates from its acellular tissue engineered vessel (ATEV) programs. Title:Humacyte Second Quarter 2024 Financial Results and Corporate UpdateDate:August 13, 2024Time:8:30 AM Eastern TimeConference Call Details:1-877-704-4453 (U.S. Investors Dial)1-201-389-0920 (International Investor
– 2nd quarter conference call to be held Tuesday, August 13th, at 8:30 a.m. ET – DURHAM, N.C., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that the U.S. Food and Drug Administration (FDA) will require additional time to complete its review of its Biologic License Application (BLA) for the acellular tissue engineered vessel (ATEV) in the vascular trauma indication. The ATEV trauma program BLA was submitted to FDA in December 2023, and the FDA granted a Priority Review in February 2024 and assigned a PDUFA date of
DURHAM, N.C., May 06, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, will release its financial results for the first quarter ended March 31, 2024, on Friday, May 10, 2024. Management will host a webcast and conference call at 8:00 a.m. ET to provide a corporate and financial update. Title:Humacyte First Quarter 2024 Financial Results and Corporate UpdateDate:May 10, 2024Time:8:00 AM Eastern TimeConference Call Details:1-877-704-4453 (U.S. Investors Dial)1-201-389-0920 (International Investors Dial)13746046 (Conference ID)Call me™ Feature: Click HereWe
4 - Humacyte, Inc. (0001818382) (Issuer)
4 - Humacyte, Inc. (0001818382) (Issuer)
4 - Humacyte, Inc. (0001818382) (Issuer)
– ATEV™ demonstrated superiority at six and 12 months (co-primary endpoints) compared to autogenous fistula, the current standard of care for hemodialysis access – - ATEV also showed superior function and patency in female, obese and diabetic patients, subgroups with historically poor outcomes with autogenous fistula procedures - DURHAM, N.C., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, announced the presentation of positive results from the V007 Phase 3 clinical trial of the acellular tissue engineered vessel (ATEV) in arteriovenous (AV)
DURHAM, N.C., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced that it will host a virtual KOL event on Thursday, October 31, 2024 at 8:00 AM ET. To register, click here. The event will feature Charles Keith Ozaki, MD (Brigham and Women's Hospital), Mohamad Anas Hussain, MD, PhD (Brigham and Women's Hospital), and Timmy Lee, MD, MSPH (University of Alabama at Birmingham), who will discuss the current treatment landscape and unmet need for improved arteriovenous (AV) access in hemodialysis patients. During the event, the
DURHAM, N.C., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, announced that its late-breaking abstract on the V007 Phase 3 clinical trial of the acellular tissue engineered vessel (ATEV™) in arteriovenous access for patients with end-stage renal disease was accepted for an oral presentation at the American Society of Nephrology's (ASN) Kidney Week 2024. The late-breaking abstract titled "Prospective Randomized Trial of Humacyte's Acellular Tissue Engineered Vessel Versus Autologous Arteriovenous Fistula for Hemodialysis Access" will be present
4 - Humacyte, Inc. (0001818382) (Issuer)
4 - Humacyte, Inc. (0001818382) (Issuer)
4 - Humacyte, Inc. (0001818382) (Issuer)
Humacyte, Inc. (NASDAQ:HUMA) stock is trending on Tuesday. In July, the company has so far added Dr. John P. Bamforth and Dr. Keith Anthony to its Board of Directors, entered a license agreement with Pluristyx and received Regenerative Medicine Advanced Therapy (RMAT) designation by the FDA for its Acellular Tissue Engineered Vessel. The Details: Humacyte acquired a license for Pluristyx’s PluriBank induced Pluripotent Stem Cell (iPSC) line to use as starting materials in the production of insulin-producing cells for their BioVascular Pancreas (BVP) product candidate. The BVP aims to treat type 1 diabetes by facilitating the delivery and survival of insulin-producing islets within the
Shares of SolarEdge Technologies, Inc. (NASDAQ:SEDG) fell sharply during Monday's session after the company announced a workforce reduction. SolarEdge disclosed a decision to lay off 400 employees. The company stated that 200 of these job cuts are in Israel. The action involves reducing headcount and discretionary spending across all departments. SolarEdge Technologies shares dipped 12.2% to $27.77 on Monday. Here are some other stocks moving in today’s mid-day session. Gainers Autonomix Medical, Inc. (NASDAQ:AMIX) shares climbed 148% to $1.4850 after the company entered into an agreement with RF Innovations to license intellectual property for its Apex 6 Radiofrequency Gener
BTIG analyst Ryan Zimmerman maintains Humacyte (NASDAQ:HUMA) with a Buy and raises the price target from $8 to $11.
SC 13D/A - Humacyte, Inc. (0001818382) (Subject)
SC 13D/A - Humacyte, Inc. (0001818382) (Subject)
SC 13D/A - Humacyte, Inc. (0001818382) (Subject)
H.C. Wainwright initiated coverage of Humacyte with a rating of Buy and set a new price target of $6.00
Piper Sandler upgraded Humacyte from Underweight to Neutral and set a new price target of $3.50 from $2.75 previously
Cantor Fitzgerald initiated coverage of Humacyte with a rating of Overweight and set a new price target of $6.00
BioAesthetics Corporation announced today the appointment of Juliana Blum, PhD as its new Chief Executive Officer, effective August 12, 2024. Dr. Sandra Coufal, MD, Director of BioAesthetics and CEO of Toragen, Inc. said, "This is an important milestone for BioAesthetics. During the development of every successful biotech company, there comes a time when the founding CEO transitions to a different role and a new CEO with different skill sets is needed for product advancement and commercialization. Dr. Blum's experience with novel products as co-founder of Humacyte will help guide further progress at BioAesthetics." Dr. Blum joins BioAesthetics following her 20 years spent as Co-founder
DURHAM, N.C., June 27, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced the appointment of Diane Seimetz, Ph.D., to its board of directors. "Diane is an innovator and strategist with extensive experience in the biopharmaceutical industry, and we are delighted to welcome her to the Humacyte board," said Kathleen Sebelius, Chair of Humacyte's board of directors. "Her expertise in guiding companies with innovative products to the market will be invaluable as Humacyte moves toward commercialization of the Human Acellular VesselTM (HAV). We al
--Seasoned physician, scientist and life science executive brings expertise in clinical research and development across product life cycle-- --Key appointment as Humacyte advances HAV through multiple late-stage clinical trials in initial vascular applications-- DURHAM, N.C., April 05, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced the appointment of Shamik J. Parikh, M.D., as Chief Medical Officer. In this role, Dr. Parikh will lead the company's global clinical development strategy, including oversight of the preclinical and clinical